Vertex Pharmaceuticals’ short interest has dropped by 22.32%, now sitting at 1.74% of its float—Wall Street seems less pessimistic. Short interest reflects how many shares are being bet against and ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.92% to $485.89 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to ...

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...

The availability of suzetrigine may represent a critical step in addressing the nation’s pain management crisis. While questions remain about its cost, adoption, and long-term efficacy, its novel ...

In a report released yesterday, Whitney Ijem from Canaccord Genuity reiterated a Buy rating on Verve Therapeutics (VERV – Research Report), ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is ...

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

Vertex Pharmaceuticals Incorporated (NASDAQ ... on diversifying its product portfolio and recently launched two new approved ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are ...